Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Roberta Mortarini, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Davide Bedognetti, View ORCID ProfileAndrea Anichini, Michele Maio, View ORCID ProfileMichele Ceccarelli the EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators
doi: https://doi.org/10.1101/2023.02.09.23285227
Teresa Maria Rosaria Noviello
1Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy
2BIOGEM Institute of Molecular Biology and Genetics, Ariano Irpino, Italy
Anna Maria Di Giacomo
3Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy
4University of Siena, Siena, Italy
5NIBIT Foundation Onlus, Italy
Francesca Pia Caruso
1Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy
2BIOGEM Institute of Molecular Biology and Genetics, Ariano Irpino, Italy
Alessia Covre
4University of Siena, Siena, Italy
Giovanni Scala
1Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy
Maria Claudia Costa
1Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy
2BIOGEM Institute of Molecular Biology and Genetics, Ariano Irpino, Italy
Sandra Coral
4University of Siena, Siena, Italy
Wolf H. Fridman
6INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team Cancer, Immune Control and Escape, Paris, France
7University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
8Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
Catherine Sautès-Fridman
6INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team Cancer, Immune Control and Escape, Paris, France
7University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
8Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
Roberta Mortarini
9Human Tumors Immunobiology Unit, Dept. of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Silvia Brich
10Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Giancarlo Pruneri
10Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Elena Simonetti
3Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy
Maria Fortunata Lofiego
4University of Siena, Siena, Italy
Davide Bedognetti
11Cancer Program, Human Immunology Department, Research Branch, Sidra Medicine, Doha, Qatar
Andrea Anichini
9Human Tumors Immunobiology Unit, Dept. of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Michele Maio
3Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy
4University of Siena, Siena, Italy
5NIBIT Foundation Onlus, Italy
Michele Ceccarelli
1Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy
2BIOGEM Institute of Molecular Biology and Genetics, Ariano Irpino, Italy
Posted February 10, 2023.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Roberta Mortarini, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Davide Bedognetti, Andrea Anichini, Michele Maio, Michele Ceccarelli
medRxiv 2023.02.09.23285227; doi: https://doi.org/10.1101/2023.02.09.23285227
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Roberta Mortarini, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Davide Bedognetti, Andrea Anichini, Michele Maio, Michele Ceccarelli
medRxiv 2023.02.09.23285227; doi: https://doi.org/10.1101/2023.02.09.23285227
Subject Area
Subject Areas
- Addiction Medicine (365)
- Allergy and Immunology (685)
- Anesthesia (183)
- Cardiovascular Medicine (2724)
- Dermatology (234)
- Emergency Medicine (411)
- Epidemiology (12378)
- Forensic Medicine (10)
- Gastroenterology (783)
- Genetic and Genomic Medicine (4233)
- Geriatric Medicine (394)
- Health Economics (698)
- Health Informatics (2732)
- Health Policy (1014)
- Hematology (369)
- HIV/AIDS (874)
- Medical Education (404)
- Medical Ethics (111)
- Nephrology (450)
- Neurology (4010)
- Nursing (216)
- Nutrition (594)
- Oncology (2112)
- Ophthalmology (602)
- Orthopedics (251)
- Otolaryngology (310)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (475)
- Pediatrics (1145)
- Primary Care Research (465)
- Public and Global Health (6630)
- Radiology and Imaging (1440)
- Respiratory Medicine (883)
- Rheumatology (418)
- Sports Medicine (350)
- Surgery (461)
- Toxicology (57)
- Transplantation (192)
- Urology (171)